<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Isoproterenol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Isoproterenol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Isoproterenol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8578" href="/d/html/8578.html" rel="external">see "Isoproterenol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11975" href="/d/html/11975.html" rel="external">see "Isoproterenol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F184870"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Isuprel [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1059534"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenergic Agonist Agent</span>;</li>
<li>
<span class="list-set-name">Antiasthmatic</span>;</li>
<li>
<span class="list-set-name">Beta<sub>1</sub> &amp; Beta<sub>2</sub>-Adrenergic Agonist Agent</span>;</li>
<li>
<span class="list-set-name">Bronchodilator</span>;</li>
<li>
<span class="list-set-name">Sympathomimetic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462482"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note</b>: Patients may exhibit dose-dependent vasodilation due to unopposed beta<sub>2</sub>-agonism elicited by isoproterenol.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d7fb5a7a-e00d-4f14-bc1f-84de404e56ab">Bradycardia; increase cardiac output</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b> Bradycardia; increase cardiac output:</b> Very limited data available: Continuous IV infusion: 0.05 to 1 mcg/<b>kg</b>/minute; titrate to effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14962334','lexi-content-ref-Eichenwald.1','lexi-content-ref-18066569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14962334','lexi-content-ref-Eichenwald.1','lexi-content-ref-18066569'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F184892"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Patients may exhibit dose-dependent vasodilation due to unopposed beta<sub>2</sub>-agonism elicited by isoproterenol.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b2c91e0f-8f40-4c1e-9f97-6c08ae122810">Bradycardia, severe; AV nodal block</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bradycardia, severe; AV nodal block: </b>Limited data available: Infants, Children, and Adolescents: Continuous IV infusion: 0.05 to 0.5 mcg<b>/kg</b>/minute; titrate to effect; doses as high as 2 mcg/<b>kg</b>/minute may be needed in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1'])">Ref</a></span>); usual adult range: 2 to 10 mcg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51128349"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51128350"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F184872"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8578" href="/d/html/8578.html" rel="external">see "Isoproterenol: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> May cause dose-dependent hypotension due to beta-2 agonist effects.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18ae4661-ec31-4c3c-83c5-d332e4c822f2">Bradycardia or atrioventricular block, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bradycardia or atrioventricular block, symptomatic (unresponsive to atropine):</b> Continuous infusion: <b>IV: </b>Usual dosage range: 1 to 20 mcg/minute; titrate to clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586772']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586772'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f2c2d9ee-9903-4ccb-aae5-c7847d18e569">Cardiogenic shock due to bradycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiogenic shock due to bradycardia (off-label use):</b> Continuous infusion: <b>IV:</b> 2 to 20 mcg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923988'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6e868d93-0673-4ddd-a96d-018294217a94">Provocation during tilt table testing, diagnostic agent for syncope</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Provocation during tilt table testing, diagnostic agent for syncope (off-label use): Note: </b>Timing of initiation and dose adjustment during test may be institution specific; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion: <b>IV: </b>Initial: 1 mcg/minute; increase as necessary based on clinical response up to 3 mcg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15519256','lexi-content-ref-29562304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15519256','lexi-content-ref-29562304'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b114f4be-776b-41ad-bb62-86924f8afe54">Torsade de pointes, to reduce recurrence</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Torsade de pointes, to reduce recurrence (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use only in patients who have a bradycardia-mediated cause of torsades de pointes. Avoid use in congenital long QT syndrome. Patient should be under the care of a clinician experienced with using isoproterenol for this condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224','lexi-content-ref-29097320']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224','lexi-content-ref-29097320'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>Continuous infusion: <b>IV:</b> Usual dosage range: 2 to 10 mcg/minute; titrate to clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224','lexi-content-ref-29097320']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224','lexi-content-ref-29097320'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990595"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987976"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F184842"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Adams-Stokes syndrome, angina pectoris, atrioventricular block (Barold 2015), bradycardia (Duong 2020), chest pain (Duong 2020), coronary artery vasospasm (Duong 2020), flushing, hypertension, hypotension (Suwa 2004), increased ST segment on ECG (Okuya 2021), palpitations, tachyarrhythmia, tachycardia, ventricular arrhythmia (including non-sustained ventricular fibrillation) (Okuya 2021), ventricular premature contractions (Okuya 2021)</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Diaphoresis, pallor</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:2em;">Nervous system: Dizziness, headache, nervousness, tremor</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Blurred vision (Duong 2020)</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Dyspnea, pulmonary edema</p></div>
<div class="block coi drugH1Div" id="F184856"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Angina, preexisting ventricular arrhythmias, tachycardia or tachyarrhythmias; cardiac glycoside intoxication induced heart block or tachycardia.</p></div>
<div class="block war drugH1Div" id="F184839"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, coronary artery disease); may increase myocardial oxygen demand resulting in ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; may transiently increase blood glucose levels.</p>
<p style="text-indent:-2em;margin-left:4em;">• Distributive shock: Avoid use in patients with distributive shock; may reduce systemic vascular resistance (SVR) further resulting in hemodynamic compromise.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older patients: Use with caution in older patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfites: Contains sulfites; may cause allergic reaction in susceptible individuals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use with extreme caution; not currently a treatment of choice. Excessive or prolonged use may result in decreased effectiveness.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878505"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Isoproterenol is not recommended for treatment of bronchospasm. In children with refractory asthma, continuous isoproterenol infusion was associated with myocardial necrosis, congestive heart failure, further clinical deterioration, and death in some cases. The risk of cardiac toxicity was observed to be increased by concomitant corticosteroids or methylxanthines, acidosis, or hypoxemia; monitor patients closely (vital signs, ECG, cardiac enzymes) with therapy.</p></div>
<div class="block foc drugH1Div" id="F184850"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isuprel: 0.2 mg/mL (1 mL [DSC], 5 mL [DSC]) [contains disodium edta]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.2 mg/mL (1 mL, 5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.2 mg/mL (1 mL, 5 mL)</p></div>
<div class="block geq drugH1Div" id="F184835"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323236"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Isoproterenol HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 mg/mL (per mL): $16.80 - $264.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867272"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.2 mg/mL (1 mL, 5 mL)</p></div>
<div class="block admp drugH1Div" id="F52613092"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Administer by continuous IV infusion; requires the use of an infusion pump</p></div>
<div class="block adm drugH1Div" id="F184853"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: IV infusion administration requires the use of an infusion pump.</p></div>
<div class="block uicp drugH1Div" id="F14472667"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 20 <b>mcg</b>/mL </p></div>
<div class="block sts drugH1Div" id="F184864"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials/ampules at 20°C to 25°C (68°F to 77°F). Protect from light; keep in opaque container until used. Exposure to air, light, or increased temperature may cause a pink to brownish pink color to develop. Solutions should not be used if they are discolored or contain a precipitate. Stability of parenteral admixture in NS or D5W at room temperature (25°C [77°F]) or at refrigeration (4°C [39°F]) for ≥24 hours has been reported (Newton 1981; van Matre 2023); also refer to institution-specific policies and procedures.</p></div>
<div class="block usep drugH1Div" id="F53567407"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Mild or transient episodes of heart block that do not require electric shock or pacemaker therapy; serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation); cardiac arrest until electric shock or pacemaker therapy is available; bronchospasm during anesthesia; adjunct to fluid and electrolyte replacement therapy and other drugs and procedures in the treatment of hypovolemic or septic shock and low cardiac output states (eg, decompensated heart failure, cardiogenic shock) (All indications: FDA approved in adults)</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> The use of isoproterenol in advanced cardiac life support (ACLS) has largely been supplanted by the use of other adrenergic agents (eg, epinephrine and dopamine). The use of isoproterenol for bronchospasm during anesthesia and cardiogenic, hypovolemic, or septic shock is no longer recommended.</p></div>
<div class="block mst drugH1Div" id="F184919"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Isuprel may be confused with Disophrol, Isordil</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299548"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of COMT</p></div>
<div class="block dri drugH1Div" id="F184844"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: May diminish the therapeutic effect of Isoproterenol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorpheniramine: May enhance the therapeutic effect of Isoproterenol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COMT Inhibitors: May increase the serum concentration of COMT Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiphenhydrAMINE (Systemic): May enhance the therapeutic effect of Isoproterenol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Isoproterenol may enhance the therapeutic effect of EPINEPHrine (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the arrhythmogenic effect of Isoproterenol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the therapeutic effect of Isoproterenol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the therapeutic effect of Isoproterenol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Isoproterenol may decrease the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F7732005"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted by the manufacturer. Use of isoproterenol may interfere with uterine contractions at term (Mahon 1967).</p></div>
<div class="block mopp drugH1Div" id="F53567384"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate, blood pressure, respiratory rate, arterial blood gases, central venous pressure, ECG, urine output; in pediatric patients, daily cardiac enzymes</p></div>
<div class="block pha drugH1Div" id="F184838"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates beta<sub>1</sub>- and beta<sub>2</sub>-receptors resulting in relaxation of bronchial, GI, and uterine smooth muscle, increased heart rate and contractility, vasodilation of peripheral vasculature</p></div>
<div class="block phk drugH1Div" id="F184855"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: IV: Immediate </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: IV: 10-15 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Via conjugation in many tissues including hepatic and pulmonary </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 2.5-5 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (primarily as sulfate conjugates)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038663"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Isoproterenol phoroneus</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Isoprenalin macure | Isuprel</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cipla isoprenaline | Isoprenaline macure</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Isoprenaline hcl macure | Isuprel</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Isoprenalin sad</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Isoprenaline macure</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Isoprenaline hydrochloride tillomed | Isuprel</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ims isoprenaline | Suscardia</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Isoprenalina</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Isoprenaline</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Isoprenalina cloridrato galenica senese | Isoprenalina cloridrato salf</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Isuprel</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aleudrina</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Isuprel</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Isoprenaline hcl macure | Isoprenalinesulfaat</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Isoprenaline macure</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Isoproterenol HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Isoprenalina macure</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Isuprel</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Isoprenaline macure</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Izoprenalin macure</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Isoproterenol | Proternol L</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29097320">
<a name="29097320"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2018;15(10):e190-e252. doi:10.1016/j.hrthm.2017.10.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/29097320/pubmed" id="29097320" target="_blank">29097320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2913492">
<a name="2913492"></a>Almquist A, Goldenberg IF, Milstein S, et al. Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. <i>N Engl J Med</i>. 1989;320(6):346-351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/2913492/pubmed" id="2913492" target="_blank">2913492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25234696">
<a name="25234696"></a>Barold SS, De Wilde HE, Timmers L, Van Heuverswyn FE, Stroobandt RX. Atrioventricular block precipitated by isoproterenol. <i>Ann Noninvasive Electrocardiol</i>. 2015;20(4):397-401. doi:10.1111/anec.12192<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/25234696/pubmed" id="25234696" target="_blank">25234696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15519256">
<a name="15519256"></a>Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope – update 2004. <i>Europace</i>. 2004;6(6):467-537. doi:10.1016/j.eupc.2004.08.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/15519256/pubmed" id="15519256" target="_blank">15519256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29562304">
<a name="29562304"></a>Brignole M, Moya A, de Lange FJ, et al; ESC Scientific Document Group. 2018 ESC guidelines for the diagnosis and management of syncope. <i>Eur Heart J</i>. 2018;39(21):1883-1948. doi:10.1093/eurheartj/ehy037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/29562304/pubmed" id="29562304" target="_blank">29562304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14962334">
<a name="14962334"></a>Castilla M, Jerez M, Llácer M, Martinez S. Anaesthetic management in a neonate with congenital complete heart block. <i>Paediatr Anaesth</i>. 2004;14(2):172-175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/14962334/pubmed" id="14962334" target="_blank">14962334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24970294">
<a name="24970294"></a>Denis A, Sacher F, Derval N, et al. Diagnostic value of isoproterenol testing in arrhythmogenic right ventricular cardiomyopathy. <i>Circ Arrhythm Electrophysiol</i>. 2014;7(4):590-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/24970294/pubmed" id="24970294" target="_blank">24970294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33078637">
<a name="33078637"></a>Duong H, Masarweh OM, Campbell G, Win TT, Joolhar F. Isoproterenol causing coronary vasospasm and ST elevations during tilt table testing. <i>J Investig Med High Impact Case Rep</i>. 2020;8:2324709620966862. doi:10.1177/2324709620966862<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/33078637/pubmed" id="33078637" target="_blank">33078637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC, Hansen AR, Martin CR, eds. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Lippincott William and Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):640-656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gropper.1">
<a name="Gropper.1"></a>Gropper M, Eriksson L, Fleisher L, Wiener-Kronish J, Cohen N, Leslie K, eds. <i>Miller's Anesthesia</i>. 9th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avet.1">
<a name="Avet.1"></a>Isoproterenol hydrochloride ampules [prescribing information]. E. Windsor, NJ: AuroMedics Pharma LLC; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avet.1">
<a name="Avet.1"></a>Isoproterenol hydrochloride vials [prescribing information]. Rancho Cucamonga, CA: Amphastar Pharmaceuticals, Inc; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avet.1">
<a name="Avet.1"></a>Isoproterenol hydrochloride vials [prescribing information]. Lincolnshire, IL: Nexus Pharmaceuticals, Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isuprel.1">
<a name="Isuprel.1"></a>Isuprel (isoproterenol) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7296791">
<a name="7296791"></a>Keren A, Tzivoni D, Gavish D, et al. Etiology, Warning Signs and Therapy of Torsade de Pointes. A Study of 10 Patients. <i>Circulation</i>. 1981;64(6):1167-1174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/7296791/pubmed" id="7296791" target="_blank">7296791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586772">
<a name="30586772"></a>Kusumoto FM, Schoenfeld MH, Barrett C, et al 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2019;140(8):e382-e482. doi:10.1161/CIR.0000000000000628<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/30586772/pubmed" id="30586772" target="_blank">30586772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6023594">
<a name="6023594"></a>Mahon WA, Reid DW, Day RA. The <i>in vivo</i> Effects of Beta Adrenergic Stimulation and Blockade on the Human Uterus at Term. <i>J Pharmacol Exp Ther</i>. 1967;156(1):178-185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/6023594/pubmed" id="6023594" target="_blank">6023594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18066569">
<a name="18066569"></a>Matsubara S, Morimatsu Y, Shiraishi H, et al. Fetus with heart failure due to congenital atrioventricular block treated by maternally administered ritodrine. <i>Arch Gynecol Obstet</i>. 2008;278(1):85-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/18066569/pubmed" id="18066569" target="_blank">18066569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation.</i> 2010;122(18)(suppl 3):7297-7267. doi:10.1161/CIRCULATIONAHA.110.970988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7282714">
<a name="7282714"></a>Newton DW, Fung EY, Williams DA. Stability of five catecholamines and terbutaline sulfate in 5% dextrose injection in the absence and presence of aminophylline. <i>Am J Hosp Pharm</i>. 1981;38(9):1314-1319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/7282714/pubmed" id="7282714" target="_blank">7282714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33162486">
<a name="33162486"></a>Okuya Y, Park JY, Garg A, Moussa I. Coronary artery spasm during catheter ablation caused by the intravenous infusion of isoproterenol. <i>Intern Med</i>. 2021;60(8):1221-1224. doi:10.2169/internalmedicine.6130-20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/33162486/pubmed" id="33162486" target="_blank">33162486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11233951">
<a name="11233951"></a>Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. <i>Med Clin North Am</i>. 2001;85(2):321-341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/11233951/pubmed" id="11233951" target="_blank">11233951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sinclair-Pingel.1">
<a name="Sinclair-Pingel.1"></a>Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Order Entry System [published correction appears in <i>Hosp Pharm</i>. 2007; 42:84-85]. <i>Hosp Pharm</i>. 2006;41:1102-1106.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15329512">
<a name="15329512"></a>Suwa S, Sumiyoshi M, Mineda Y, Ohta H, Kojima S, Nakata Y. Vasovagal response induced by a low dose of isoproterenol infusion before tilting-up. <i>Circ J</i>. 2004;68(9):876-877. doi:10.1253/circj.68.876<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/15329512/pubmed" id="15329512" target="_blank">15329512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28923988">
<a name="28923988"></a>van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/28923988/pubmed" id="28923988" target="_blank">28923988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36890952">
<a name="36890952"></a>Van Matre ET, Rice PJ, Wempe MF, Lyda C, Kiser TH. Extended stability of isoproterenol hydrochloride injection in polyvinyl chloride bags stored in amber ultraviolet light blocking bags. <i>Hosp Pharm</i>. 2023;58(2):183-187. doi:10.1177/00185787221125722<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/36890952/pubmed" id="36890952" target="_blank">36890952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20007991">
<a name="20007991"></a>Woods BD, Sladen RN. Perioperative considerations for the patient with asthma and bronchospasm. <i>Br J Anaesth</i>. 2009;103(suppl 1):i57-i65. doi:10.1093/bja/aep271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/20007991/pubmed" id="20007991" target="_blank">20007991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36325905">
<a name="36325905"></a>Wyckoff MH, Greif R, Morley PT, et al; Collaborators. 2022 International Consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations: summary from the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces. <i>Circulation</i>. 2022;146(25):e483-e557. doi:10.1161/CIR.0000000000001095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoproterenol-pediatric-drug-information/abstract-text/36325905/pubmed" id="36325905" target="_blank">36325905</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13394 Version 263.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
